Genolution

Genolution Free Cash Flow

The Free Cash Flow (FCF) of Genolution (225220.KQ) as of Oct 22, 2026 is -7.45 B KRW. In the previous year, Free Cash Flow (FCF) was -13.62 B KRW — a change of -45.27% (higher).

Free Cash Flow

-7.45 BKRW

YoY

-45.27%

Last updated:

Free Cash Flow (FCF) of Genolution is 2025 -7.45 B KRW. Free Cash Flow (FCF) of Genolution was 2024 -13.62 B KRW. It decreases by -45.27% higher compared to the previous year.

The Genolution Free Cash Flow history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Free Cash Flow
Date
Free Cash Flow
Jan 1, 2018
-2.78 B KRW
Jan 1, 2019
-3.23 B KRW
Jan 1, 2020
37.29 B KRW
Jan 1, 2021
20.60 B KRW
Jan 1, 2022
-8.99 B KRW
Jan 1, 2023
-8.02 B KRW
Jan 1, 2024
-13.62 B KRW
Jan 1, 2025
-7.45 B KRW
The Genolution Free Cash Flow history
YEARFree Cash FlowYoY
-7.45 BKRW-45.27%
-13.62 BKRW+69.84%
-8.02 BKRW-10.84%
-8.99 BKRW-143.66%
20.60 BKRW-44.75%
37.29 BKRW-1,256.12%
-3.23 BKRW+16.18%
-2.78 BKRW+1,821.29%
-144.49 MKRW-62.30%
-383.27 MKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Genolution Stock analysis

What does Genolution do? Genolution Inc develops automated nucleic acid extraction devices, nucleic acid extraction reagents, and molecular diagnostic products. The company also offers ribonucleic acid interference services. Its products are distributed domestically and internationally, serving customers in the biotechnology and healthcare sectors. The firm generates revenue through the sale of these products and services to research institutions, laboratories, and healthcare providers. The company's core offerings include nucleic acid extractors, reagents, and diagnostic products, which are used in molecular biology and medical diagnostics. Genolution Inc targets biotech firms, hospitals, and research facilities as key buyers of its technology. Its domestic market presence complements its international distribution channels. Genolution Inc's business model relies on selling its automated extraction devices and reagents to customers requiring efficient nucleic acid processing solutions. The company's molecular diagnostic products cater to healthcare applications, while its ribonucleic acid interference services support advanced research needs. Revenue streams are derived from both product sales and service contracts within the biotechnology industry. Genolution is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Genolution stock

Free Cash Flow (FCF) of Genolution is -7.45 B KRW in 2025.

Free Cash Flow (FCF) of Genolution changed from -13.62 B KRW to -7.45 B KRW, representing a -45.27% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow (FCF) Genolution since 2006 – with annual values, charts, and detailed analysis.

Free Cash Flow is the cash available after capital expenditures. It represents the cash a company can use for dividends, debt reduction, or reinvestment.

FCF = Operating Cash Flow - Capital Expenditures

Free Cash Flow (FCF)'s KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Free Cash Flow (FCF)'s Genolution historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Genolution

All Key Metrics — Genolution